Will tonix Pharmaceuticals stock go up?
The Wall Street analyst predicted that TONIX PHARMACEUTICALS HOLDING's share price could reach $0.60 by Apr 18, 2023. The average TONIX PHARMACEUTICALS HOLDING stock price prediction forecasts a potential upside of 244.83% from the current TNXP share price of $0.17.
Why did tonix Pharmaceuticals stock crash?
The big decline came after Tonix announced on Friday following the market close that it is halting enrollment in a late-stage clinical study evaluating TNX-102 SL in treating fibromyalgia.Jul 26, 2021
Is tonix Pharmaceuticals a good stock to buy?
Tonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
What happened to Tonix Pharmaceuticals stock in 2016?
Shares of Tonix $TNXP were halted in pre-market trading. But once Nasdaq hit the play button, Tonix tanked over 77%. Although the Phase III trial crashed and burned, the company still has hopes for a reconfigured pivotal study, pointing to data at 4 weeks that showed some early promise.Jul 27, 2018
Will tonix reverse split?
(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on November 1, 2019.Oct 31, 2019
Where is tonix Pharmaceuticals located?
Chatham, New jerseyTonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in Chatham, New jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
How high does IDEX go?
On average, analysts forecast that IDEX's EPS will be -$0.17 for 2022, with the lowest EPS forecast at -$0.26, and the highest EPS forecast at -$0.09. On average, analysts forecast that IDEX's EPS will be -$0.07 for 2023, with the lowest EPS forecast at -$0.07, and the highest EPS forecast at -$0.07.
Signals & Forecast
Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Tonix Pharmaceuticals Holding Corp.
Support, Risk & Stop-loss
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Is Tonix Pharmaceuticals Holding Corp. stock A Buy?
Tonix Pharmaceuticals Holding Corp. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
How many groups of primates received TNX-1800?
The study in question pitted TNX-1800 against a control vaccine called TNX-801 in nonhuman primates divided into five groups of four: Two groups received the TNX-1800 at two different doses, two more groups received TNX-801 at two doses, and the last group received a placebo.
What is Prosper's passion?
Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math.
When will Tonix be added to the Russell 3000?
CHATHAM, N.J., June 28, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tonix was added to the broad-market Russell 3000® index and the small-cap Russell 2000® Index, effective after the U.S. market opens today, June 28, 2021, as part of the annual reconstitution of the Russell stock indexes. "Tonix is pleased to be included in the Russell indexes which reflects our positive achie
What is TNX 102?
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) plans to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for Long COVID Syndrome (Long COVID), which is now known officially as Post-Acute Sequelae of COVID-19 (PASC1). Tonix plans to meet the FDA in Q3 of 2021 to seek agreement on designing a potential Phase 2 study and the overall clinical development plan. TNX-102 SL is in the second Phase 3 trial (RALLY) for fibromyalgia. The interim analysis results are expected in Q3 of 2021, an
When will New to the Street be on TV in 2021?
NEW YORK, June 25, 2021 (GLOBE NEWSWIRE) -- FMW Media’s New to The Street TV announces the broadcasting of its business TV show, Saturday, June 26, 2021 on Bloomberg TV at 6:00 PM ET. New to The Street’s TV line-up features the following 5-Companies and their businesses representatives: 1).
When is the 2021 Raymond James Human Health Innovation Conference?
CHATHAM, N.J., June 16, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the Raymond James Human Health Innovation Conference on June 23, 2021, at 8:00 a.m. ET. Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the Raymond James c
1 TNXP Stock's Price Graph & Average Annual Return
Below is a graph showing closing prices of Tonix Pharmaceuticals Holding Corp (TNXP) for the past 10 years. The below chart uses adjusted close instead of market close prices. (Adjusted close factors in corporate or institutional level actions outside the market.)
2 How Tonix Pharmaceuticals Holding Corp (TNXP) Stock Performed Against The Entire Stock Market
You should not evaluate a stock in isolation. Rather, you will benefit more if you assess the performance against broad indices and similar stocks.
4 10 Biggest One-Day Losses
Let us now see 10 biggest one-day losses of Tonix Pharmaceuticals Holding Corp (TNXP) stock.
Conclusion
Hopefully, the above report helps you learn about the past ten-year performance of Tonix Pharmaceuticals Holding Corp (TNXP) shares. Kindly use the sections below to suggest corrections or improvements to the report.
Want to become a smart investor?
Netcials reports section helps you with deep insights into the performance of various assets over the years. We are constantly upgrading and updating our reports section. Feel free to access them. Do not forget to leave your feedback.
Brittany Meiling
After scoring two promising FDA designations on its lead drug, tiny Tonix Pharmaceuticals is aborting its late-stage study in PTSD due to lousy results — nearly flat-lining the company’s stock Friday morning.
Luca Issi
Genetic medicine, the delivery of genetic material as a therapeutic, has attracted record-breaking capital in biotech with ~$150 billion invested across ventures, IPOs, follow-ons, and M&A since 2013.
Amber Tong
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Kyle Blankenship
Looking to scuffle with rare disease giant and now AstraZeneca subsidiary Alexion, little Apellis scored a breakthrough win earlier this summer for its own complement factor inhibitor drug. Apellis, though, always had its eyes on bigger fish, but a first glimpse at pivotal data for a major indication has muddied the waters.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.
Zachary Brennan
Overshadowed by President Biden’s vaccine mandate announcement, the administration earlier in the day released its top priorities for drug pricing reforms making their way through Congress.
John Carroll
One of Paul Hudson’s picks for Sanofi’s pipeline has gone down in defeat in a Phase III trial.
Where is Tonix Pharmaceuticals located?
Tonix Pharmaceuticals is based in New York and specializes in producing drugs that treat specific central nervous system conditions. “These results underscore the challenges in designing and conducting well-controlled clinical studies in PTSD, especially military-related PTSD.
Is Tonix a Phase 2 drug?
In addition to its Tonmya drug, Tonix is currently working on a bedtime treatment drug for agitation in Alz heimer’s disease, which is currently in its Phase 2 of its trial.
Is Tonix halting Phase 3?
Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP) announced this morning that it would be halting its Phase 3 study of its Tonmya drug, which caused its stock price to drop in dramatic fashion.